Cutaneous T-cell lymphoma recurrent – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:21:52 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Cutaneous T-cell lymphoma recurrent – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A Study of PTX-100 for Patients with Cutaneous T-Cell Lymphoma That Has Returned or Did Not Respond to Previous Treatment https://clinicaltrials.eu/trial/a-study-of-ptx-100-for-patients-with-cutaneous-t-cell-lymphoma-that-has-returned-or-did-not-respond-to-previous-treatment/ Wed, 29 Apr 2026 15:07:59 +0000 https://clinicaltrials.eu/trial/a-study-of-ptx-100-for-patients-with-cutaneous-t-cell-lymphoma-that-has-returned-or-did-not-respond-to-previous-treatment/ This study is looking at Cutaneous T-Cell Lymphoma, which is a type of cancer where certain white blood cells called T-cells become abnormal and affect the skin. The study will test a treatment called PTX-100, which is given through a vein as an infusion. This medication works by targeting specific processes in cancer cells to help stop their growth. The study specifically includes patients who have Mycosis fungoides or Sezary syndrome, which are the most common forms of this disease, as well as some other subtypes of this lymphoma. The treatment will be given on its own, without combining it with other cancer medications.

The purpose of this study is to determine how well PTX-100 works in treating this type of lymphoma in patients whose disease has come back or has not responded to previous treatments. The study will also look at how safe the medication is and how the body processes it. Patients in this study will have already tried at least two other treatments for their disease that either did not work or caused problems they could not tolerate. These previous treatments might have included medications such as interferon, chemotherapy drugs like methotrexate, or other specialized cancer treatments.

During the study, doctors will carefully monitor how the disease responds to PTX-100 by checking skin lesions, measuring abnormal cells in the blood, and looking at any disease that has spread beyond the skin. The study will track various measures including how many patients respond to treatment, how long the response lasts, how long patients live without the disease getting worse, and overall survival. Safety will be monitored throughout by checking for side effects, doing blood tests, measuring vital signs, and performing heart tests called electrocardiograms. Blood samples will also be taken at different times to understand how the body absorbs and processes the medication.

]]> Study on the Safety of Mogamulizumab for Patients with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome https://clinicaltrials.eu/trial/study-on-the-safety-of-mogamulizumab-for-patients-with-relapsed-or-refractory-mycosis-fungoides-or-sezary-syndrome/ Wed, 29 Apr 2026 14:58:50 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-of-mogamulizumab-for-patients-with-relapsed-or-refractory-mycosis-fungoides-or-sezary-syndrome/ This clinical trial is focused on studying a type of cancer called Cutaneous T-Cell Lymphoma (CTCL), specifically the subtypes known as Mycosis Fungoides and Sézary Syndrome. These are rare forms of cancer that affect the skin. The treatment being tested in this study is a medication called Mogamulizumab, which is also known by its code names KW-0761 and AMG 761. This medication is given as an infusion, which means it is administered directly into the bloodstream through a vein.

The purpose of the study is to evaluate the safety and tolerability of Mogamulizumab when given every four weeks to participants whose cancer has returned or has not responded to previous treatments. Participants will receive the medication over a period of up to 24 weeks. During the study, researchers will monitor participants for any side effects and changes in their health, including laboratory tests and physical examinations.

This study aims to gather important information about how the body responds to Mogamulizumab and to understand its effects on the cancer. The study will also look at how the medication is processed in the body and whether the immune system produces any antibodies against it. This information will help determine the potential benefits and risks of using Mogamulizumab for treating Cutaneous T-Cell Lymphoma.

]]> Study of Lacutamab Alone or with Chemotherapy for Patients with Advanced T-Cell Lymphoma https://clinicaltrials.eu/trial/study-of-lacutamab-alone-or-with-chemotherapy-for-patients-with-advanced-t-cell-lymphoma/ Wed, 29 Apr 2026 14:29:49 +0000 https://clinicaltrials.eu/trial/study-of-lacutamab-alone-or-with-chemotherapy-for-patients-with-advanced-t-cell-lymphoma/ This clinical trial is focused on studying a type of cancer called T-cell lymphoma, which includes specific subtypes such as Cutaneous T-cell lymphoma and Mycosis fungoides. These are advanced forms of cancer that affect the skin and other parts of the body. The treatment being tested in this study is a medication called Lacutamab, also known by its code name IPH4102. Lacutamab is a type of protein treatment known as a monoclonal antibody, which is designed to target and attack cancer cells. The study will explore the effects of Lacutamab when used alone or in combination with chemotherapy.

The purpose of this study is to evaluate how well patients respond to the treatment. Participants will receive Lacutamab through an intravenous infusion, which means the medication is given directly into a vein. The study will monitor the participants over a period to see how their cancer responds to the treatment. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of Lacutamab. The study will also assess the safety of the treatment and any side effects that may occur.

Throughout the study, researchers will collect information on how the treatment affects the participants’ quality of life and overall health. This includes monitoring any changes in symptoms and conducting regular health checks. The study aims to provide valuable insights into the effectiveness of Lacutamab for treating advanced T-cell lymphoma and to determine if it can be a beneficial treatment option for patients with this type of cancer.

]]>